EDAP, Telix explore PSMA PET and HIFU collaboration

EDAP TMS and Telix Pharmaceuticals have signed a letter of intent to explore clinical research and physician education around prostate cancer care.

The proposed collaboration would combine EDAP’s Focal One Robotic HIFU system with Telix’s PSMA PET imaging products. The companies said the initial investigational focus will be integrating PSMA PET diagnostic scans into the Focal One HIFU treatment workflow.

The goal is to use PSMA PET to optimize treatment planning, guide focal therapy, and monitor response after treatment and during follow-up. The work is expected to include both the primary treatment setting and salvage treatment after radiation therapy.

Focal One uses high-intensity focused ultrasound for robotic focal therapy in prostate cancer. Telix’s PSMA PET agents are used to visualize prostate cancer by targeting prostate-specific membrane antigen expression, which can help clinicians localize disease and assess treatment-relevant findings.

The companies said the collaboration builds on early clinical experience combining PSMA PET with Focal One HIFU, along with the prospective HIFI-2 study evaluating Focal One in patients with recurrence after radiation therapy. EDAP said the combination could help standardize treatment strategies and personalize focal therapy.

“We are uniquely designed to enable the integration of PSMA PET imaging with Focal One’s real-time ultrasound and fully robotic energy delivery,” said Ryan Rhodes, EDAP chief executive officer.

Telix announced a broader set of collaborations May 15 involving EDAP and Profound Medical. Those initiatives are intended to explore PSMA PET imaging across emerging minimally invasive and image-guided prostate cancer treatment approaches, including robotic HIFU and transurethral ultrasound ablation.

The Telix announcement identifies Gozellix and Illuccix, both kits for preparing gallium Ga 68 gozetotide, as the PSMA PET imaging agents involved in the planned research. The company said the initial focus is patient selection, treatment planning, post-treatment monitoring, and evidence generation to inform best practice.

Kevin Richardson, CEO of Telix Precision Medicine, said PSMA PET imaging may help clinicians make treatment decisions across minimally invasive and image-guided prostate cancer approaches.

The parties may also explore clinician education programs, including webinars, symposia, and training initiatives. Clinical studies could involve shared customers managing patients with Telix PSMA PET imaging products and Focal One Robotic HIFU.

The letter of intent is not a definitive agreement. EDAP said there is no assurance that specific initiatives will result from the collaboration, and the letter does not require either party to enter into future agreements. No financial commitments were made, and the collaboration is not expected to materially affect EDAP’s financial results.

For imaging specialists, the announcement reflects a broader shift in prostate cancer care: molecular imaging is moving beyond staging and recurrence detection into treatment selection, procedural planning, and longitudinal response monitoring.